Please assess the completion status of the following clinical trial:

Trial Title: Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Vulvovaginal candidiasis infection is diagnosed, the symptoms evaluated using a numerical rating system based on severity (absent=0; mild=1; moderate=2; severe=3) with a minimum VVC Composite Signs/Symptoms score of 7~* Subject completes the informed consent process~* Subject agrees to take study medication when scheduled~* Subject complies with all clinical trial instructions. Commits to all follow-up visits~* Subject agrees to abstain from sexual intercourse from the time of randomization through the first seven days immediately following treatment~Exclusion Criteria:~* had any other sexually transmitted disease or gynaecological abnormality requiring treatment~* had a disease known to predispose to candidiasis such as diabetes mellitus, or were receiving antibiotics or corticosteriods~* had used antifungal medication in the week before entry; or~* were expected to menstruate within seven days of the start of treatment~* infected more than one candida species

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 48 Years
- Healthy Volunteers: f

Study Arms:
- Terconazole Vaginal Suppository (Type: EXPERIMENTAL): Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days
- Fluconazole (Type: ACTIVE_COMPARATOR): orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.

Based on this trial design, predict the completion outcome and termination type (if applicable).